Adding pioglitazone to insulin and SGLT2 inhibitor for type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether adding a diabetes pill called pioglitazone to your current treatment (which includes an SGLT2 inhibitor and insulin) can lower your HbA1c (average blood sugar) further and prevent a dangerous rise in blood ketones, a byproduct that can cause serious complications. If it works, this combination may help improve blood sugar control in people with type 1 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years.
- You have type 1 diabetes.
- You are treated with insulin pump or multiple daily insulin injections.
- Your total daily insulin dose is at least 0.6 units per kilogram of body weight.
- Your HbA1c (average blood sugar over 3 months) is between 7.0% and 11.0%.
- Your kidney function is adequate (eGFR ≥ 60).
- Your weight is stable and you don't do excessively heavy exercise.
- You are otherwise in good health (no major medical conditions besides diabetes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding certain diabetes pills (GLP-1 receptor agonists or SGLT inhibitors) to insulin is safe and helpful for adults with type 1 diabetes. Doctors will check your glucose monitor data to see how well this works.
This trial tests how two diabetes medications, SGLT2i and pioglitazone, affect ketone production in people with type 1 diabetes. It aims to find new ways to improve blood sugar control.
This study is testing two different diabetes pills—dapagliflozin or pioglitazone—in people with type 2 diabetes. The goal is to see which one works better when added to your current metformin and DPP-4 inhibitor. You may qualify if your blood sugar is not well controlled with your current medications.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This study tests whether adding a sodium-glucose cotransporter-2 inhibitor (SGLT2i), a thiazolidinedione (TZD), or a combination of both to your current DPP4 inhibitor-based treatment can improve blood sugar control in type 2 diabetes. It aims to find the best add-on option for people who need extra help managing their diabetes.
This study tests a medication called dapagliflozin, which is usually for type 2 diabetes, to see if it can be used safely in people with type 1 diabetes. It focuses on preventing a serious side effect called ketoacidosis, where the blood becomes too acidic.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.